(CHCT) Community Healthcare Trust - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US20369C1062
Stock: Medical Offices, Clinics, Ambulatory Centers, Specialty Facilities
Total Rating 32
Risk 38
Buy Signal -0.02
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 12.02% |
| Yield on Cost 5y | 5.67% |
| Yield CAGR 5y | 2.24% |
| Payout Consistency | 100.0% |
| Payout Ratio | 288.1% |
| Risk 5d forecast | |
|---|---|
| Volatility | 29.3% |
| Relative Tail Risk | -3.58% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.06 |
| Alpha | -6.94 |
| Character TTM | |
|---|---|
| Beta | 0.384 |
| Beta Downside | 0.524 |
| Drawdowns 3y | |
|---|---|
| Max DD | 60.66% |
| CAGR/Max DD | -0.30 |
Description: CHCT Community Healthcare Trust December 27, 2025
Community Healthcare Trust Inc. (CHCT) is a U.S. health-care REIT that owns roughly $1.2 billion of income-producing outpatient facilities across 200 properties in 36 states, encompassing about 4.6 million sq ft as of September 30 2025. The portfolio includes one sales-type lease and two assets classified as held-for-sale, reflecting a focus on long-term, triple-net lease structures tied to outpatient service delivery.
Key operating metrics from the most recent quarterly report show an occupancy rate of ~96% and a funds-from-operations (FFO) growth of 5% year-over-year, driven by strong demand for outpatient care amid an aging U.S. population and the continued shift from inpatient to ambulatory services. The REIT’s weighted-average lease term remains above 10 years, and its dividend yield sits near 5.8%, while leverage is modest at a debt-to-EBITDA ratio of roughly 3.2×, indicating financial resilience in a rising-interest-rate environment.
For a deeper dive into CHCT’s valuation dynamics and how its exposure to demographic and policy trends may affect future performance, you might find ValueRay’s analyst toolkit useful.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: -7.49m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 0.69 > 1.0 |
| NWC/Revenue: -192.4% < 20% (prev -75.15%; Δ -117.2% < -1%) |
| CFO/TA 0.06 > 3% & CFO 56.6m > Net Income -7.49m |
| Net Debt (530.8m) to EBITDA (62.9m): 8.43 < 3 |
| Current Ratio: 0.17 > 1.5 & < 3 |
| Outstanding Shares: last quarter (26.9m) vs 12m ago 1.03% < -2% |
| Gross Margin: 80.64% > 18% (prev 0.62%; Δ 8002 % > 0.5%) |
| Asset Turnover: 12.12% > 50% (prev 11.78%; Δ 0.34% > 0%) |
| Interest Coverage Ratio: 0.72 > 6 (EBITDA TTM 62.9m / Interest Expense TTM 26.4m) |
Altman Z'' -1.68
| A: -0.23 (Total Current Assets 48.4m - Total Current Liabilities 277.9m) / Total Assets 987.3m |
| B: 0.08 (Retained Earnings 76.3m / Total Assets 987.3m) |
| C: 0.02 (EBIT TTM 18.9m / Avg Total Assets 984.5m) |
| D: -0.51 (Book Value of Equity -288.1m / Total Liabilities 560.4m) |
| Altman-Z'' Score: -1.68 = D |
Beneish M -3.48
| DSRI: 0.76 (Receivables 36.6m/46.9m, Revenue 119.3m/115.6m) |
| GMI: 0.77 (GM 80.64% / 61.82%) |
| AQI: 1.01 (AQ_t 0.95 / AQ_t-1 0.94) |
| SGI: 1.03 (Revenue 119.3m / 115.6m) |
| TATA: -0.06 (NI -7.49m - CFO 56.6m) / TA 987.3m) |
| Beneish M-Score: -3.48 (Cap -4..+1) = AA |
What is the price of CHCT shares?
As of February 07, 2026, the stock is trading at USD 18.13 with a total of 154,138 shares traded.
Over the past week, the price has changed by +4.92%, over one month by +8.95%, over three months by +26.92% and over the past year by +1.95%.
Over the past week, the price has changed by +4.92%, over one month by +8.95%, over three months by +26.92% and over the past year by +1.95%.
Is CHCT a buy, sell or hold?
Community Healthcare Trust has received a consensus analysts rating of 4.00.
Therefore, it is recommended to buy CHCT.
- StrongBuy: 2
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CHCT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 18.3 | 0.7% |
| Analysts Target Price | 18.3 | 0.7% |
| ValueRay Target Price | 19.3 | 6.5% |
CHCT Fundamental Data Overview February 05, 2026
P/E Forward = 37.3134
P/S = 4.1797
P/B = 1.1707
Revenue TTM = 119.3m USD
EBIT TTM = 18.9m USD
EBITDA TTM = 62.9m USD
Long Term Debt = 274.1m USD (from longTermDebt, last quarter)
Short Term Debt = 256.0m USD (from shortTermDebt, last quarter)
Debt = 534.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 530.8m USD (from netDebt column, last quarter)
Enterprise Value = 1.03b USD (499.7m + Debt 534.1m - CCE 3.38m)
Interest Coverage Ratio = 0.72 (Ebit TTM 18.9m / Interest Expense TTM 26.4m)
EV/FCF = 27.52x (Enterprise Value 1.03b / FCF TTM 37.4m)
FCF Yield = 3.63% (FCF TTM 37.4m / Enterprise Value 1.03b)
FCF Margin = 31.39% (FCF TTM 37.4m / Revenue TTM 119.3m)
Net Margin = -6.28% (Net Income TTM -7.49m / Revenue TTM 119.3m)
Gross Margin = 80.64% ((Revenue TTM 119.3m - Cost of Revenue TTM 23.1m) / Revenue TTM)
Gross Margin QoQ = 80.76% (prev 80.80%)
Tobins Q-Ratio = 1.04 (Enterprise Value 1.03b / Total Assets 987.3m)
Interest Expense / Debt = 1.32% (Interest Expense 7.08m / Debt 534.1m)
Taxrate = 21.0% (US default 21%)
NOPAT = 15.0m (EBIT 18.9m * (1 - 21.00%))
Current Ratio = 0.17 (Total Current Assets 48.4m / Total Current Liabilities 277.9m)
Debt / Equity = 1.25 (Debt 534.1m / totalStockholderEquity, last quarter 426.8m)
Debt / EBITDA = 8.43 (Net Debt 530.8m / EBITDA 62.9m)
Debt / FCF = 14.17 (Net Debt 530.8m / FCF TTM 37.4m)
Total Stockholder Equity = 450.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -0.76% (Net Income -7.49m / Total Assets 987.3m)
RoE = -1.66% (Net Income TTM -7.49m / Total Stockholder Equity 450.5m)
RoCE = 2.61% (EBIT 18.9m / Capital Employed (Equity 450.5m + L.T.Debt 274.1m))
RoIC = 1.57% (NOPAT 15.0m / Invested Capital 953.5m)
WACC = 4.08% (E(499.7m)/V(1.03b) * Re(7.33%) + D(534.1m)/V(1.03b) * Rd(1.32%) * (1-Tc(0.21)))
Discount Rate = 7.33% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 1.82%
[DCF Debug] Terminal Value 85.52% ; FCFF base≈34.7m ; Y1≈32.1m ; Y5≈29.1m
Fair Price DCF = 12.10 (EV 875.4m - Net Debt 530.8m = Equity 344.6m / Shares 28.5m; r=5.90% [WACC]; 5y FCF grow -9.43% → 2.90% )
EPS Correlation: -47.84 | EPS CAGR: -8.74% | SUE: -0.41 | # QB: 0
Revenue Correlation: 91.85 | Revenue CAGR: 7.81% | SUE: 0.03 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.10 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=1
EPS next Year (2026-12-31): EPS=0.47 | Chg30d=+0.000 | Revisions Net=-1 | Growth EPS=+295.8% | Growth Revenue=+5.8%
P/S = 4.1797
P/B = 1.1707
Revenue TTM = 119.3m USD
EBIT TTM = 18.9m USD
EBITDA TTM = 62.9m USD
Long Term Debt = 274.1m USD (from longTermDebt, last quarter)
Short Term Debt = 256.0m USD (from shortTermDebt, last quarter)
Debt = 534.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 530.8m USD (from netDebt column, last quarter)
Enterprise Value = 1.03b USD (499.7m + Debt 534.1m - CCE 3.38m)
Interest Coverage Ratio = 0.72 (Ebit TTM 18.9m / Interest Expense TTM 26.4m)
EV/FCF = 27.52x (Enterprise Value 1.03b / FCF TTM 37.4m)
FCF Yield = 3.63% (FCF TTM 37.4m / Enterprise Value 1.03b)
FCF Margin = 31.39% (FCF TTM 37.4m / Revenue TTM 119.3m)
Net Margin = -6.28% (Net Income TTM -7.49m / Revenue TTM 119.3m)
Gross Margin = 80.64% ((Revenue TTM 119.3m - Cost of Revenue TTM 23.1m) / Revenue TTM)
Gross Margin QoQ = 80.76% (prev 80.80%)
Tobins Q-Ratio = 1.04 (Enterprise Value 1.03b / Total Assets 987.3m)
Interest Expense / Debt = 1.32% (Interest Expense 7.08m / Debt 534.1m)
Taxrate = 21.0% (US default 21%)
NOPAT = 15.0m (EBIT 18.9m * (1 - 21.00%))
Current Ratio = 0.17 (Total Current Assets 48.4m / Total Current Liabilities 277.9m)
Debt / Equity = 1.25 (Debt 534.1m / totalStockholderEquity, last quarter 426.8m)
Debt / EBITDA = 8.43 (Net Debt 530.8m / EBITDA 62.9m)
Debt / FCF = 14.17 (Net Debt 530.8m / FCF TTM 37.4m)
Total Stockholder Equity = 450.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -0.76% (Net Income -7.49m / Total Assets 987.3m)
RoE = -1.66% (Net Income TTM -7.49m / Total Stockholder Equity 450.5m)
RoCE = 2.61% (EBIT 18.9m / Capital Employed (Equity 450.5m + L.T.Debt 274.1m))
RoIC = 1.57% (NOPAT 15.0m / Invested Capital 953.5m)
WACC = 4.08% (E(499.7m)/V(1.03b) * Re(7.33%) + D(534.1m)/V(1.03b) * Rd(1.32%) * (1-Tc(0.21)))
Discount Rate = 7.33% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 1.82%
[DCF Debug] Terminal Value 85.52% ; FCFF base≈34.7m ; Y1≈32.1m ; Y5≈29.1m
Fair Price DCF = 12.10 (EV 875.4m - Net Debt 530.8m = Equity 344.6m / Shares 28.5m; r=5.90% [WACC]; 5y FCF grow -9.43% → 2.90% )
EPS Correlation: -47.84 | EPS CAGR: -8.74% | SUE: -0.41 | # QB: 0
Revenue Correlation: 91.85 | Revenue CAGR: 7.81% | SUE: 0.03 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.10 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=1
EPS next Year (2026-12-31): EPS=0.47 | Chg30d=+0.000 | Revisions Net=-1 | Growth EPS=+295.8% | Growth Revenue=+5.8%